Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.73 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | OSBP | P22059 | 1/20 | 0.68 |
| ▸ | RORC | P51449 | 1/20 | 0.68 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.68 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.61 |
| ▸ | GBA1 | P04062 | 2/20 | 0.60 |
| ▸ | UGCG | Q16739 | 2/20 | 0.60 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27101999 | 1.00 | POLA1 (0.73) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL8425524 | 1.00 | POLA1 (0.73) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL28404863 | 1.00 | POLA1 (0.73) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL8961810 | 1.00 | POLA1 (0.73) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL8608988 | 0.99 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL8839992 | 0.99 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL28273010 | 0.99 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL11497304 | 0.99 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL28088865 | 0.99 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3954236 | 0.98 | POLA1 (0.76) | POLA1CYP46A1USP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390238-A1 | MINIMALIST EMULSION COMPOSITIONS | ICB (an ABC), LLC | 2024-11-28 | — | — | US | claimed |
| CN-119015394-A | Sulfur-containing compound preparation, and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240342084-A1 | TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USE | DONAGHYS LIMITED (NZ) | 2024-10-17 | — | — | US | claimed |
| US-12053545-B2 | Transdermal solvent system and methods of use | DONAGHYS LIMITED (NZ) | 2024-08-06 | — | — | US | claimed |
| US-20240180868-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRUS INFECTION, THE PHARMACEUTICAL COMPOSITION COMPRISING ROTTLERIN AS ACTIVE INGREDIENT | QVET (KR) | 2024-06-06 | — | — | US | claimed |
| CN-118078678-A | Cosmetic composition for lips comprising an ester and/or a ceramide | 株式会社爱茉莉太平洋 | 2024-05-28 | — | — | CN | claimed |
| CN-117597118-A | Pharmaceutical composition for preventing or treating viral infection comprising as active ingredient a crude drug | QVET公司 | 2024-02-23 | — | — | CN | claimed |
| EP-4321158-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS, CONTAINING ROTTLERIN AS ACTIVE INGREDIENT | Qvet (KR) | 2024-02-14 | — | — | EP | claimed |
| CN-116889513-A | Water-in-oil emulsion composition | 花王株式会社 | 2023-10-17 | — | — | CN | claimed |
| WO-2023049939-A1 | MINIMALIST EMULSION COMPOSITIONS | BAEK CLINICAL INC. (US) | 2023-03-30 | — | — | WO | claimed |
| US-20220287944-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE INC (US) | 2022-09-15 | — | — | US | claimed |
| US-20220241196-A1 | TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USE | DONAGHYS LIMITED (NZ) | 2022-08-04 | — | — | US | claimed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| EP-3999032-A1 | TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USE | Donaghys Limited (NZ) | 2022-05-25 | — | — | EP | claimed |
| US-11324695-B2 | Transdermal solvent system and methods of use | DONAGHYS LIMITED (NZ) | 2022-05-10 | — | — | US | claimed |
| CN-109490533-B | Pepsinogen II (PG II) detection kit and production process thereof | 南京澳林生物科技有限公司 | 2022-02-15 | — | — | CN | claimed |
| US-20260144718-A1 | SOLID POWDER COSMETIC | KOSE CORPORATION (JP) | 2026-05-28 | — | — | US | disclosed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| WO-2022019640-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING GRAPHENE NANOPARTICLES | 바이오그래핀 주식회사 | 2022-01-27 | — | — | WO | disclosed |
| EP-3328981-B1 | CLEANSING COMPOSITION WITH IMPROVED AVAILABILITY OF BENEFIT AGENT | UNILEVER GLOBAL IP LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390238-A1 | MINIMALIST EMULSION COMPOSITIONS | ADH7, PROC, OTC | POLA1 142/4885CYP46A1 1599/4885USP2 3398/4885 |
| US-20260144718-A1 | SOLID POWDER COSMETIC | CUTA, CFB, FLNB | POLA1 2394/4885CYP46A1 2330/4885USP2 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.